Source: Annual Congress 2012 - New insights in the pathology of lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
F. Tian, J. Mysliwietz, J. Ellwart, A. Tufman, A. Bergner, R. Huber (Munich, Germany). LSC 2012 abstract – Effects of the Hedgehog (Hh) pathway inhibitor GDC-0449 on lung cancer cells and cisplatin resistant lung cancer cells are mediated by lung cancer stem cells (SPs). Eur Respir J 2012; 40: Suppl. 56, 4543

Member's Comments

No comment yet.

Related content which might interest you: CDCA promotes non-small-cell lung cancer (NSCLC) migration by regulating Akt/Erk1/2 signaling pathways Source: International Congress 2019 – Thoracic oncology: Treatment, diagnostic options and biology Year: 2019 Bevacizumab (Avastin®) aerosol therapy (AT) inhibits primary and metastatic tumor growth in a murine model with human non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Efficacy of Afatinib, Erlotinib, and Gefitinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients with brain metastasis: a network meta-analysis Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 Shikonin-induced necroptosis is enhanced by the inhibition of autophagy in non-small cell lung cancer cells Source: International Congress 2016 – Basic science and case reports in lung cancer Year: 2016 Cyclooxygenase(COX)-2 is over-expressed in non small cell lung cancer (NSCLC) and is a potential target for treatment Source: Eur Respir J 2002; 20: Suppl. 38, 400s Year: 2002 HIF-1α modulation by topoisomerase inhibitors in A549, a non-small cell lung cancer cell line Source: Annual Congress 2007 - Biology in thoracic oncology Year: 2007 Specific plasmids encoding shRNA molecules directed against growth factor receptors in cell proliferation inhibition and induction phenotype changes relevant to enhancement of anti-tumor immunity. Model of human non-small (NSCLC) and small (SCLC) cell lung cancer lines Source: Annual Congress 2010 - Pathology of lung cancer Year: 2010 Late Breaking Abstract: Effect of the hedgehog pathway inhibitor GDC-0449 on side populations in lung cancer cell lines Source: Annual Congress 2010 - Clinical diagnosis and management of malignant pleural effusions Year: 2010 Adaptation to hypoxia leads to apoptosis resistance to cisplatin in non-small cell lung cancer (NSCLC) cell line Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008 Simvastatin overcomes gefitinib resistance in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor via Akt/b-catenin signaling dependent down-regulation of survivin Source: Annual Congress 2013 –Basic research on lung cancer Year: 2013 MiR-34a favours macrophage polarization switch from M2 to M1 phenotype in non small cell lung cancer (NSCLC) Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020 LSC 2013 abstract - NF-κbeta acts downstream of EGFR in regulating low dose cadmium induced primary lung cell proliferation Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013 Inhibition of the effect of epidermal growth factor (EGF) on lung cancer cells. The use of plasmids encoding specific siRNA molecules Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer Year: 2015 LATE-BREAKING ABSTRACT: Expression of macrophage migration inhibitory factor (MIF) in the serum and lung tissues in patients with non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Dihydroartemisinin combined with cisplatinum induced apoptosis and related mechanism research in human lung adenocarcinoma H1299 cells Source: International Congress 2016 – Lung cancer and immune cells: friends or foes? Year: 2016 Functional expressions of EGFP/LKB1 and its kinase domain induced apoptosis and enhanced chemosensitivity in lung cancer cell lines Source: Eur Respir J 2004; 24: Suppl. 48, 5s Year: 2004 Gefitinib selectively targets non-small cell lung cancer cells through inhibition of Forkhead box M1 Source: Annual Congress 2011 - Treatment of lung cancer Year: 2011 LSC - 2017 - CREB signaling in KRAS-driven lung adenocarcinoma Source: International Congress 2017 – Lung cancer: latest basic research on molecular alterations, tumour-immune system-microenvironment interplay and the metabolome Year: 2017 Targeting gene of insulin-like growth factor type I (IGF-I) on in vitro model of A549 cell line with triple-helix approach. Perspectives of gene therapy in non-small cell lung (NSCLC) cancer Source: Eur Respir J 2006; 28: Suppl. 50, 387s Year: 2006 C-erbB-3 expression in non small cell lung cancer (NSCLC) patients treated by erlotinib Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010